

Provisional 2025 EPHMRA ATC Developments

The following new class structures were voted on by EPHMRA/Intellus in May/June 2024 and agreed in principle. These structures will now be used in the next part of the development process which is the detailed refinement of the rules.

Please note that these new class structures are provisional at this time. The 2025 codes, descriptions and Guideline text will be finalised and published by the Committee at the end of 2024. The new structures then come into effect from the beginning of 2025.

Other hormones – anticorticosteroids

New third level class within H4 (Other hormones) for products containing anticorticosteroids, including products for Cushing’s syndrome. Currently, these products are classified in H4X (Other hormones and preparations with similar actions).

| | |
|------------|---|
| H4G | ANTICORTICOSTEROID PRODUCTS |
| | <p>Products containing anticorticosteroids, eg ketoconazole, levoketoconazole, mifepristone, osilodrostat, etc for Cushing’s syndrome only are classified here.</p> <p>Products containing ketoconazole for other conditions are classified elsewhere. Products containing mifepristone for contraception or gynaecological conditions are classified in G3A6 or G3X.</p> <p>Products containing pasireotide for both Cushing’s syndrome and acromegaly are classified in H1C2. Products containing metyrapone for both treatment and diagnosis of Cushing’s syndrome are classified in T2X9. Products containing anticorticosteroids for cardiovascular conditions, for example eplerenone, spironolactone etc, are classified in C3A.</p> |

Immunoglobulins – respiratory syncytial virus

New fourth level class within J6H (Specific immunoglobulins - antiviral) for immunoglobulins for the prevention of respiratory syncytial virus (RSV) e.g. nirsevimab or palivizumab. Currently, these products are classified in J6H9 (Other antiviral immunoglobulins).

| | |
|-------------|---------------------------|
| J6H6 | RSV immunoglobulin |
|-------------|---------------------------|

Immunoglobulins – COVID-19

New fourth level class within J6H (Specific immunoglobulins - antiviral) for COVID-19 immunoglobulins e.g. casirivimab + imdevimab and cilgavimab + tixagevimab. Currently, these products are classified in J6H9 (Other antiviral immunoglobulins).

| | |
|-------------|---|
| J6H7 | COVID-19 immunoglobulin |
| | Monoclonal antibodies for prevention/post-exposure prophylaxis, and for both prevention/post-exposure prophylaxis and treatment of COVID-19 are classified here. Monoclonal antibodies for treatment only of COVID-19 are classified in J5B6. |

Vaccines – respiratory syncytial virus

New fourth level class within J7E (Viral vaccines) for respiratory syncytial virus (RSV) vaccines. Currently, these products are classified in J7E9 (All other viral vaccines).

| | |
|-------------|---------------------|
| J7E7 | RSV vaccines |
|-------------|---------------------|

Gabapentinoids

New third level class within N2 (Analgesics) for products containing gabapentinoids. Currently, these products are predominantly classified in N3A (Anti-epileptics), however mirogabalin is classified in N2B (Non-narcotics and anti-pyretics) as it is only indicated for neuropathic pain.

| | |
|------------|--|
| N2D | GABAPENTINOID PRODUCTS |
| | Includes products containing gabapentinoids, eg gabapentin, gabapentin enacarbil, mirogabalin, pregabalin, etc. Gabapentinoids for epilepsy, generalised anxiety disorder, neuropathic pain, restless leg syndrome etc are classified here. Combinations of gabapentinoids with other substances are classified here. |